PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-51.02%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-46.54%
Negative gross profit growth while MRVL is at 3.82%. Joel Greenblatt would examine cost competitiveness or demand decline.
-9.60%
Negative EBIT growth while MRVL is at 8.09%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-55.20%
Negative operating income growth while MRVL is at 15.99%. Joel Greenblatt would press for urgent turnaround measures.
80.95%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
81.13%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
81.13%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.19%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.19%
Diluted share reduction more than 1.5x MRVL's 1.17%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-3.21%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
316.99%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
184.15%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
-28.67%
Negative 10Y revenue/share CAGR while MRVL stands at 56.20%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-39.49%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-62.42%
Negative 3Y CAGR while MRVL stands at 25.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
64.38%
5Y OCF/share CAGR 1.25-1.5x MRVL's 45.44%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
39.55%
3Y OCF/share CAGR at 50-75% of MRVL's 63.72%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-185.06%
Negative 10Y net income/share CAGR while MRVL is at 653.69%. Joel Greenblatt sees a major red flag in long-term profit erosion.
70.38%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-115.93%
Negative 3Y CAGR while MRVL is 202.86%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
91.70%
10Y equity/share CAGR above 1.5x MRVL's 54.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
88.43%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
33.93%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
1.01%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
19.89%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
42.45%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
-17.25%
Firm’s AR is declining while MRVL shows 11.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-29.91%
Inventory is declining while MRVL stands at 4.05%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.06%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-0.62%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
6.74%
Debt growth far above MRVL's 3.89%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-55.80%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-10.69%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.